Evidence map›Paper›PMID 40471488›Full record

ArticleEndocrine2025

Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries.

Francesco Panzuto, Alessandro Gallo, Marco Marini, Maria Rinzivillo, Manuela Albertelli, Chiara Maria Grana, Marco Maccauro, Massimo Milione, Salvatore Tafuto, Simona Barbi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco PanzutoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome. Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy. Francesco.panzuto@uniroma1.it.ORCID 0000-0003-2789-4289
Alessandro GalloSpringer Healthcare, Milano, Italy.
Marco MariniInstitute of Cognitive Sciences and Technologies, National Research Council, Rome, Italy.
Maria RinzivilloDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome. Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy.
Manuela AlbertelliEndocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy.
Chiara Maria GranaRadiometabolic Therapy, Nuclear Medicine Division, IRCCS IEO Milano, Milano, Italy.
Marco MaccauroNuclear Medicine Department, Foundation IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Massimo MilioneDepartment of Diagnostic Innovation, Istituto Nazionale Tumori IRCCS, Milan, Italy.
Salvatore TafutoDepartment of Sarcomas and Rare Tumors, Istituto Nazionale Tumori - IRCCS, Fondazione G. Pascale, Naples, Italy.
Simona BarbiNET Italy patient association, Bologna, Italy.
Stefano PartelliDepartment of Sarcomas and Rare Tumors, Istituto Nazionale Tumori - IRCCS, Fondazione G. Pascale, Naples, Italy.
Italian Association for Neuroendocrine Tumors AI study group
NET-Italy patient advocacy group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLarge Language Models (LLMs) are increasingly used in oncology, but their application in neuroendocrine neoplasms (NENs) is still unexplored.

aimTo evaluate the accuracy, clarity, and completeness of LLM responses to clinically relevant NEN management questions. MATERIAL AND

methodsA study was conducted from October to December 2024, during which a team of experts posed nine key NEN management questions to three LLMs: ChatGPT Plus, Microsoft Copilot, and Perplexity. Responses were assessed by 22 expert physicians across specialties using a 5-point Likert scale based on scientific accuracy, clarity, and completeness, and additionally evaluated by 24 NEN patients for clarity and relevance. Primary outcomes included LLM performance across evaluation criteria and factors influencing ratings, analyzed using a linear mixed-effects model.

resultsChatGPT Plus scored highest (M = 3.72, SE = 0.19), followed by Copilot (M = 3.54, SE = 0.19) and Perplexity (M = 3.22, SE = 0.19), with clarity rating the highest. The chemotherapy indications question received the lowest scores, underscoring LLM challenges in handling complex clinical decisions. DISCUSSION: This study highlights LLMs' potential in NEN management as informative tools with clear but variably accurate responses. Continuous improvement and clinician oversight are essential for their successful integration into patient communication.

Indexed as

Artificial IntelligenceNeuroendocrine TumorsPatient-Centered CareFemaleHumansMaleMiddle AgedArtificial intelligenceChatGPTManagementNeuroendocrine tumors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.